Terms: = Prostate cancer AND BRD4, O60885, 23476, ENSG00000141867, HUNKI, CAP, MCAP AND Treatment
579 results:
1. Myeloid-derived suppressor cells attenuate the antitumor efficacy of radiopharmaceutical therapy using
Muralidhar A; Hernandez R; Morris ZS; Comas Rojas H; Bio Idrissou M; Weichert JP; McNeel DG
J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38663936
[TBL] [Abstract] [Full Text] [Related]
2. Ductal, intraductal, and cribriform carcinoma of the prostate: Molecular characteristics and clinical management.
Shi Y; Wang H; Golijanin B; Amin A; Lee J; Sikov M; Hyams E; Pareek G; Carneiro BA; Mega AE; Lagos GG; Wang L; Wang Z; Cheng L
Urol Oncol; 2024 May; 42(5):144-154. PubMed ID: 38485644
[TBL] [Abstract] [Full Text] [Related]
3. Functional and oncologic outcomes of prostate capsule-sparing radical cystectomy: A systematic review and meta-analysis.
Dall CP; Mason JB; Goldman CC; Fabrizio G; Alagha EC; Chou J; Kowalczyk KJ; Agarwal PK; Stamatakis L; Krasnow RE
Urol Oncol; 2024 May; 42(5):121-132. PubMed ID: 38418269
[TBL] [Abstract] [Full Text] [Related]
4. Revolutionizing localized prostate cancer treatment: Stereotactic radiotherapy "Moroccan experience".
Naim A; Lahlou Z; Kaanouch O; Heddat A; Mansouri S
Arch Ital Urol Androl; 2024 Feb; 96(1):12104. PubMed ID: 38363238
[TBL] [Abstract] [Full Text] [Related]
5. The Ability of the STAR-cap Staging System to Prognosticate the Risk of Subsequent Therapies and Metastases After Initial treatment of M0 prostate cancer.
Sung D; Schmidt B; Tward JD
Clin Genitourin Cancer; 2024 Apr; 22(2):426-433.e5. PubMed ID: 38290900
[TBL] [Abstract] [Full Text] [Related]
6. Magnetic resonance imaging-ultrasound fusion guided focal cryoablation for men with intermediate-risk prostate cancer.
Sidana A; Tayebi S; Blank F; Lama DJ; Meyer M; Saeed Y; Tobler J; Hsu WW; Verma S
Urol Oncol; 2024 May; 42(5):158.e1-158.e10. PubMed ID: 38245407
[TBL] [Abstract] [Full Text] [Related]
7. Discovery of Novel Inhibitors of brd4 for Treating prostate cancer: A Comprehensive Case Study for Considering Water Networks in Virtual Screening and Drug Design.
Zhong H; Wang X; Chen S; Wang Z; Wang H; Xu L; Hou T; Yao X; Li D; Pan P
J Med Chem; 2024 Jan; 67(1):138-151. PubMed ID: 38153295
[TBL] [Abstract] [Full Text] [Related]
8. Myeloid differentiation factor-2/LY96, a potential predictive biomarker of metastasis and poor outcomes in prostate cancer: clinical implications as a potential therapeutic target.
Ferrari MG; Jimenez-Uribe AP; Wang L; Hoeppner LH; Murugan P; Hahm E; Yu J; Kuzel TM; Gradilone SA; Mansini AP
Oncogene; 2024 Feb; 43(7):484-494. PubMed ID: 38135694
[TBL] [Abstract] [Full Text] [Related]
9. A single-center, multi-factor, retrospective study to improve the diagnostic accuracy of primary prostate cancer using [
Lv J; Yu H; Yin H; Shi Y; Shi H
Eur J Nucl Med Mol Imaging; 2024 Feb; 51(3):919-927. PubMed ID: 37940684
[TBL] [Abstract] [Full Text] [Related]
10. A new histone deacetylase inhibitor remodels the tumor microenvironment by deletion of polymorphonuclear myeloid-derived suppressor cells and sensitizes prostate cancer to immunotherapy.
Chen Z; Yang X; Chen Z; Li M; Wang W; Yang R; Wang Z; Ma Y; Xu Y; Ao S; Liang L; Cai C; Wang C; Deng T; Gu D; Zhou H; Zeng G
BMC Med; 2023 Oct; 21(1):402. PubMed ID: 37880708
[TBL] [Abstract] [Full Text] [Related]
11. Lupeol, an androgen receptor inhibitor, enhances the chemosensitivity of prostate cancer stem cells to antiandrogen enzalutamide-based therapy.
Khan MA; Singh D; Jameel M; Maurya SK; Singh S; Akhtar K; Siddique HR
Toxicol Appl Pharmacol; 2023 Nov; 478():116699. PubMed ID: 37777120
[TBL] [Abstract] [Full Text] [Related]
12. Discovery of potent pyrrolo-pyrimidine and purine HDAC inhibitors for the treatment of advanced prostate cancer.
Moi D; Bonanni D; Belluti S; Linciano P; Citarella A; Franchini S; Sorbi C; Imbriano C; Pinzi L; Rastelli G
Eur J Med Chem; 2023 Nov; 260():115730. PubMed ID: 37633202
[TBL] [Abstract] [Full Text] [Related]
13. Functional implications and therapeutic targeting of androgen response elements in prostate cancer.
Senapati D; Sharma V; Rath SK; Rai U; Panigrahi N
Biochimie; 2023 Nov; 214(Pt B):188-198. PubMed ID: 37460038
[TBL] [Abstract] [Full Text] [Related]
14. Does testosterone replacement therapy increase the risk of conversion to treatment in patients with prostate cancer on active surveillance?
Daza J; Ahmad A; Shabir U; Jing Z; Shiekh M; Kauffman E; Guru KA; Hussein AA
Urol Oncol; 2023 Oct; 41(10):429.e1-429.e7. PubMed ID: 37423815
[TBL] [Abstract] [Full Text] [Related]
15. Estimating the Impact of the Inflation Reduction Act on the Out-of-Pocket Costs for Medicare Beneficiaries With Advanced prostate cancer.
Cortese BD; Dusetzina SB; Al Hussein Al Awamlh B; Penson DF; Chang SS; Barocas DA; Luckenbaugh AN; Scarpato KR; Moses KA; Talwar R
Urol Pract; 2023 Sep; 10(5):476-483. PubMed ID: 37409930
[TBL] [Abstract] [Full Text] [Related]
16. Long-term complications and health-related quality of life outcomes after radical prostatectomy with or without subsequent radiation treatment for prostate cancer.
Baskin A; Cowan JE; Braun A; Lonergan PE; Mohamad O; Washington SL; Zhao S; Broering JM; Cooperberg MR; Breyer BN; Carroll PR
Urol Oncol; 2023 Oct; 41(10):429.e9-429.e14. PubMed ID: 37407420
[TBL] [Abstract] [Full Text] [Related]
17. Deregulated kinase action in prostate cancer: molecular basis and therapeutic implications.
Singh N; Heemers HV
Endocr Relat Cancer; 2023 Sep; 30(9):. PubMed ID: 37279256
[TBL] [Abstract] [Full Text] [Related]
18. Androgen receptor blockade resistance with enzalutamide in prostate cancer results in immunosuppressive alterations in the tumor immune microenvironment.
Xu P; Yang JC; Chen B; Nip C; Van Dyke JE; Zhang X; Chen HW; Evans CP; Murphy WJ; Liu C
J Immunother Cancer; 2023 May; 11(5):. PubMed ID: 37147019
[TBL] [Abstract] [Full Text] [Related]
19. Nanotherapeutic Approach to Delivery of Chemo- and Gene Therapy for Organ-Confined and Advanced Castration-Resistant prostate cancer.
Sharma S; Mahajan SD; Chevli K; Schwartz SA; Aalinkeel R
Crit Rev Ther Drug Carrier Syst; 2023; 40(4):69-100. PubMed ID: 37075068
[TBL] [Abstract] [Full Text] [Related]
20. Financial toxicity of oral therapies in advanced prostate cancer.
Joyce DD; Dusetzina SB
Urol Oncol; 2023 Sep; 41(9):363-368. PubMed ID: 37029039
[TBL] [Abstract] [Full Text] [Related]
[Next]
